← Human Trials & Peer-Reviewed Studies
Comparison of the usefulness of Doppler-derived deceleration time versus plasma brain natriuretic peptide to predict left ventricular remodeling after mechanical revascularization in patients with ST-elevation acute myocardial infarction and left ventricular systolic dysfunction
Plain-language guide to PMID 15820157 (2005): clinical trial of BNP (Nesiritide) in 11 women.
Key Facts
- PMID
- 15820157
- Journal
- The American journal of cardiology
- Year
- 2005
- Study type
- Clinical Trial
- Authors
- Cerisano G et al. (9 authors)
- DOI
- 10.1016/j.amjcard.2004.12.029
What This Study Did, in Plain Language
What Was Tested
This clinical trial looks at BNP (Nesiritide).
The correlation between Doppler deceleration time (DT) and brain natriuretic peptide (BNP) and their predictive value for detecting left ventricular (LV) remodeling in patients who are treated with primary percutaneous intervention for infarction and LV dysfunction are unknown.
Fifty-six patients (64 +/- 12 years of age; 11 women) who had a first ST-segment elevation myocardial infarction and systolic dysfunction that was successfully treated with direct primary coronary intervention underwent 2-dimensional Doppler echocardiographic and plasma BNP evaluation at days 1 and 3 and 1 and 6 months after the index infarction.
Who Took Part
The abstract describes 11 women taking part.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
What Was Measured
The correlation between Doppler deceleration time (DT) and brain natriuretic peptide (BNP) and their predictive value for detecting left ventricular (LV) remodeling in patients who are treated with primary percutaneous intervention for infarction and LV dysfunction are unknown.
Fifty-six patients (64 +/- 12 years of age; 11 women) who had a first ST-segment elevation myocardial infarction and systolic dysfunction that was successfully treated with direct primary coronary intervention underwent 2-dimensional Doppler echocardiographic and plasma BNP evaluation at days 1 and 3 and 1 and 6 months after the index infarction.
Topics PubMed links to this paper include Angioplasty, Balloon, Coronary, Coronary Angiography, Creatine, Echocardiography, Doppler, Forecasting, Myocardial Infarction and Myocardial Revascularization.
What This Means in Plain Language
This is a clinical trial of BNP (Nesiritide) in 11 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2005 (The American journal of cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.